Mouse Model for Human Pancreatic Ductal Adenocarcinoma

人胰腺导管腺癌小鼠模型

• 批准号: 6929917
• 负责人: Gloria Huei-Ting Su
• 金额: $ 26.4万
• 依托单位: COLUMBIA UNIVERSITY HEALTH SCIENCES
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-09-01 至 2009-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6929917
• 关键词: adenocarcinoma; biotechnology; disease /disorder model; gene expression; gene targeting; genetic models; genetically modified animals; laboratory mouse; model design /development; neoplasm /cancer genetics; pancreas neoplasms; tumor suppressor genes

DESCRIPTION (provided by applicant): Pancreatic cancer is the fifth leading cause of cancer death in this country and it is almost uniformly fatal. The poor prognosis of pancreatic cancer patients can be attributed to the lack of early detections and effective treatments. Efforts to fight pancreatic cancer have been hampered by the absence of a good animal model of pancreatic cancer. A reliable mouse model is urgently needed. Tremendous progress has been made in understanding the molecular genetics of human pancreatic adenocarcinoma within the last decade. It is now clear that pancreatic cancer is a genetic disease; the tumor-suppressor genes most frequently inactivated include pl6/INK4a and SMAD4/DPC4, while oncogene HER-2/neu/ERBB2 is often overexpressed in human pancreatic adenocarcinoma. This valuable information can be utilized to create mouse models that directly mirror human pancreatic adenocarcinoma. The main objective of the project is to create mouse models of ductal pancreatic adenocarcinoma. Here we propose three complementary strategies to accomplish this goal. The first aim is to create a conditionally deleted p16 mouse. The second aim is to characterize SMAD4/MT-TGFalpha mice. Our third aim targets HER-2. HER-2 is upregulated at early stage of pancreatic tumorigenesis. We reason that pancreas-specific expression of HER-2 in a transgenic mouse line would provide the necessary first-hit to complement our p16 and SMAD4 knock-out mice. Our strategies emphasize the uses of conditional gene targeting, which would allow pancreas-specific gene regulation and tumor development, and avoid the development of undesirable phenotypes in mice. The urgency to detect and treat this deadly disease has prompted the NCI to issue a Progress Review Group report, in which the NCI identifies the development of an animal model of pancreatic cancer as one of its research priorities. This proposal is 100% pancreatic cancer relevant.

描述（由申请人提供）：胰腺癌是该国癌症死亡的第五大原因，几乎都是致命的。胰腺癌患者的预后差可归因于缺乏早期发现和有效治疗。由于缺乏良好的胰腺癌动物模型，对抗胰腺癌的努力受到阻碍。迫切需要一种可靠的小鼠模型。在过去的十年中，对人类胰腺癌的分子遗传学研究取得了巨大进展。现在清楚的是，胰腺癌是一种遗传性疾病;最常失活的肿瘤抑制基因包括p16/INK 4a和SMAD 4/DPC 4，而癌基因HER-2/neu/ERBB 2通常在人胰腺癌中过表达。这些有价值的信息可用于创建直接反映人类胰腺癌的小鼠模型。该项目的主要目标是建立胰腺导管癌的小鼠模型。在这里，我们提出了三个互补的战略来实现这一目标。第一个目标是创建条件性缺失的p16小鼠。第二个目的是表征SMAD 4/MT-TGF α小鼠。我们的第三个目标是HER-2。HER-2在胰腺肿瘤发生的早期即表达上调。我们的理由是，HER-2在转基因小鼠系中的胰腺特异性表达将提供必要的第一次打击，以补充我们的p16和SMAD 4基因敲除小鼠。我们的策略强调使用条件性基因靶向，这将允许胰腺特异性基因调控和肿瘤发展，并避免小鼠中不良表型的发展。检测和治疗这种致命疾病的紧迫性促使NCI发布了一份进展审查小组报告，其中NCI将胰腺癌动物模型的开发确定为其研究重点之一。这个建议与胰腺癌100%相关。